MENS Key Statistics, Chart & Performance
The current stock price of MENS is 2.53 USD. In the past month the price decreased by -8.99%.
MENS Technical Analysis
MENS Financial Highlights
Over the last trailing twelve months MENS reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 24.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MENS Forecast & Estimates
MENS Ownership
About MENS
Company Profile
Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
Company Info
JYONG BIOTECH LTD
23F-3, No.95, Section 1, Xintai 5th, Xizhi District
Taipei NEW TAIPEI TW
Employees: 29
Phone: 886227325205
JYONG BIOTECH LTD / MENS FAQ
What does MENS do?
Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
What is the current price of MENS stock?
The current stock price of MENS is 2.53 USD. The price decreased by -15.95% in the last trading session.
Does MENS stock pay dividends?
MENS does not pay a dividend.
What is the ChartMill technical and fundamental rating of MENS stock?
MENS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for MENS stock?
JYONG BIOTECH LTD (MENS) currently has 29 employees.
Can you provide the ownership details for MENS stock?
You can find the ownership structure of JYONG BIOTECH LTD (MENS) on the Ownership tab.